An investigational type 1 interferon receptor inhibitor was associated with significant reduction in disease activity in patients with systemic lupus erythematosus.
Study findings from EULAR 2020 suggest that higher albumin levels provide a potentially protective effect on mental health in juvenile SLE.
Converting genotype information into an interpretable probability value for five different inflammatory arthritis-causing diseases could potentially improve the diagnostic efficiency of rheumatic disease.
Careful consideration should be taken before using hydroxychloroquine in patients with diabetes, particularly in the context of COVID-19.
The WHO has suspended use of the antimalarial drug hydroxychloroquine in a clinical trial of treatments of COVID-19 after a study revealed that patients taking the drug are at increased risk for death and serious heart problems.
Hydroxychloroquine does not improve outcomes in COVID-19.
Between one-fifth and one-third of patients with rheumatoid arthritis, connective tissue disease, and vasculitis have ocular complications.
In a special article from the American College of Physicians, practice points are presented to guide the use of chloroquine or hydroxychloroquine in the setting of COVID-19.
Patients with chronic hepatitis C (HCV) achieving sustained virologic response to pegylated interferon plus ribavirin therapy did not exhibit an effect on the incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis.
A study of chloroquine in novel coronavirus 2019 (COVID-19) patients was halted due to potentially deadly side effects.